Top

Published in:

01-08-2020 | Breast Cancer | Preclinical study

PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells

Authors: Eun Ji Ro, Seung-Hee Ryu, Eun-Young Park, Je-Won Ryu, Sang Jun Byun, Seung-Ho Heo, Kang Hyun Kim, In-Jeoung Baek, Byung Ho Son, Sang-Wook Lee

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

This study evaluates the oncogenic role of PIBF1 in triple-negative breast cancer (TNBC). TNBC is considered to have a poorer prognosis than other types of breast cancer and is associated with high risk of recurrence and distant metastasis. Currently, there are no effective therapies for the TNBC patients with distant metastasis due to the lack of targeted therapeutic options.

Methods

The effects of PIBF1 knockdown on the cell viability and motility of TNBC cell lines were investigated. Effects of PIBF1 overexpression on tumorigenicity and cell motility were confirmed using Ba/F3 cell line and xenograft study on BALB/c nude mice.

Results

In TNBC cell lines that highly express PIBF1, knockdown of PIBF1 induces apoptosis and suppresses cell viability and motility with activation of the ATR/CHK1 signaling pathway. Moreover, the oncogenic function of PIBF1 was confirmed using the Ba/F3 cell line.

Conclusion

For the first time, these findings clarify the role of PIBF1 in regulating ATR/CHK1 signaling pathway and inhibiting the proliferation and migration of TNBC cell lines. These results demonstrate the oncogenic roles of PIBF1 and provide new insights into the function and the molecular mechanism of PIBF1 in malignant TNBC.

Ponde NF, Zardavas D, Piccart M (2019) Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 16(1):27–44. https://doi.org/10.1038/s41571-018-0089-9 CrossRefPubMed

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674–690. https://doi.org/10.1038/nrclinonc.2016.66 CrossRefPubMedPubMedCentral

Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412 CrossRef

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045 CrossRefPubMed

Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176–198. https://doi.org/10.1158/2159-8290.CD-18-1177 CrossRefPubMedPubMedCentral

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389 CrossRefPubMed

O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205–214. https://doi.org/10.1056/NEJMoa1011418 CrossRefPubMed

Patil M, Pabla N, Dong Z (2013) Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci 70(21):4009–4021. https://doi.org/10.1007/s00018-013-1307-3 CrossRefPubMedPubMedCentral

Thanasoula M, Escandell JM, Suwaki N, Tarsounas M (2012) ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. EMBO J 31(16):3398–3410. https://doi.org/10.1038/emboj.2012.191 CrossRefPubMedPubMedCentral

10.

Wilsker D, Bunz F (2009) Chk1 phosphorylation during mitosis: a new role for a master regulator. Cell Cycle 8(8):1161–1163. https://doi.org/10.4161/cc.8.8.8148 CrossRefPubMedPubMedCentral

11.

Matsuyama M, Goto H, Kasahara K, Kawakami Y, Nakanishi M, Kiyono T, Goshima N, Inagaki M (2011) Nuclear Chk1 prevents premature mitotic entry. J Cell Sci 124(Pt 13):2113–2119. https://doi.org/10.1242/jcs.086488 CrossRefPubMed

12.

Lam MH, Liu Q, Elledge SJ, Rosen JM (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6(1):45–59. https://doi.org/10.1016/j.ccr.2004.06.015 CrossRefPubMed

13.

Huang B, Faucette AN, Pawlitz MD, Pei B, Goyert JW, Zhou JZ, El-Hage NG, Deng J, Lin J, Yao F, Dewar RS 3rd, Jassal JS, Sandberg ML, Dai J, Cols M, Shen C, Polin LA, Nichols RA, Jones TB, Bluth MH, Puder KS, Gonik B, Nayak NR, Puscheck E, Wei WZ, Cerutti A, Colonna M, Chen K (2017) Interleukin-33-induced expression of PIBF1 by decidual B cells protects against preterm labor. Nat Med 23(1):128–135. https://doi.org/10.1038/nm.4244 CrossRefPubMed

14.

Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Chaouat G (1989) Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction. Cell Immunol 122(2):281–294. https://doi.org/10.1016/0008-8749(89)90077-4 CrossRefPubMed

15.

Check JH, Check D (2019) Therapy aimed to suppress the production of the immunosuppressive protein progesterone induced blocking factor (PIBF) may provide palliation and/or increased longevity for patients with a variety of different advanced cancers: a review. Anticancer Res 39(7):3365–3372. https://doi.org/10.21873/anticanres.13479 CrossRefPubMed

16.

Szekeres-Bartho J, Polgar B (2010) PIBF: the double edged sword. Pregnancy and tumor. Am J Reprod Immunol 64(2):77–86. https://doi.org/10.1111/j.1600-0897.2010.00833.x CrossRefPubMed

17.

Check JH, Dix E, Sansoucie L (2009) Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein. Med Hypotheses 72(1):87–90. https://doi.org/10.1016/j.mehy.2008.05.042 CrossRefPubMed

18.

Gutierrez-Rodriguez A, Hansberg-Pastor V, Camacho-Arroyo I (2017) Proliferative and invasive effects of progesterone-induced blocking factor in human glioblastoma cells. Biomed Res Int 2017:1295087. https://doi.org/10.1155/2017/1295087 CrossRefPubMedPubMedCentral

19.

Kyurkchiev D, Naydenov E, Tumangelova-Yuzeir K, Ivanova-Todorova E, Belemezova K, Bochev I, Minkin K, Mourdjeva M, Velikova T, Nachev S, Kyurkchiev S (2014) Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF). Cell Mol Neurobiol 34(4):479–489. https://doi.org/10.1007/s10571-014-0031-3 CrossRefPubMed

20.

Halasz M, Polgar B, Berta G, Czimbalek L, Szekeres-Bartho J (2013) Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity. Cell Mol Life Sci 70(23):4617–4630. https://doi.org/10.1007/s00018-013-1404-3 CrossRefPubMed

21.

Lachmann M, Gelbmann D, Kalman E, Polgar B, Buschle M, Von Gabain A, Szekeres-Bartho J, Nagy E (2004) PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int J Cancer 112(1):51–60. https://doi.org/10.1002/ijc.20326 CrossRefPubMed

22.

Marquina-Sanchez B, Gonzalez-Jorge J, Hansberg-Pastor V, Wegman-Ostrosky T, Baranda-Avila N, Mejia-Perez S, Camacho-Arroyo I, Gonzalez-Arenas A (2017) The interplay between intracellular progesterone receptor and PKC plays a key role in migration and invasion of human glioblastoma cells. J Steroid Biochem Mol Biol 172:198–206. https://doi.org/10.1016/j.jsbmb.2016.10.001 CrossRefPubMed

23.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267–273. https://doi.org/10.1038/ng1180 CrossRef

24.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. https://doi.org/10.1073/pnas.0506580102 CrossRefPubMed

25.

Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J, Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M (2014) Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 13:141. https://doi.org/10.1186/1476-4598-13-141 CrossRefPubMedPubMedCentral

26.

Iijima Y, Okuda K, Tojo A, Tri NK, Setoyama M, Sakaki Y, Asano S, Tokunaga K, Kruh GD, Sato Y (2002) Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG. Oncogene 21(28):4374–4383. https://doi.org/10.1038/sj.onc.1205544 CrossRefPubMed

27.

Demoulin JB, Dachy G, Arts FA (2017) Unwanted acquired mutations in Ba/F3 transformation assays. Oncotarget 8(13):20523–20524. https://doi.org/10.18632/oncotarget.16268 CrossRefPubMedPubMedCentral

28.

Kong K, Ng PK, Scott KL (2017) Ba/F3 transformation assays. Oncotarget 8(22):35488–35489. https://doi.org/10.18632/oncotarget.17828 CrossRefPubMedPubMedCentral

29.

Watanabe-Smith K, Godil J, Agarwal A, Tognon C, Druker B (2017) Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations. Oncotarget 8(8):12596–12606. https://doi.org/10.18632/oncotarget.15392 CrossRefPubMedPubMedCentral

30.

Holtan SG, Creedon DJ, Haluska P, Markovic SN (2009) Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 84(11):985–1000. https://doi.org/10.1016/S0025-6196(11)60669-1 CrossRefPubMedPubMedCentral

31.

Paulovich AG, Toczyski DP, Hartwell LH (1997) When checkpoints fail. Cell 88(3):315–321. https://doi.org/10.1016/s0092-8674(00)81870-x CrossRefPubMed

32.

Barnum KJ, O'Connell MJ (2014) Cell cycle regulation by checkpoints. Methods Mol Biol 1170:29–40. https://doi.org/10.1007/978-1-4939-0888-2_2 CrossRefPubMedPubMedCentral

33.

Broustas CG, Lieberman HB (2014) DNA damage response genes and the development of cancer metastasis. Radiat Res 181(2):111–130. https://doi.org/10.1667/RR13515.1 CrossRefPubMedPubMedCentral

34.

Pabla N, Bhatt K, Dong Z (2012) Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proc Natl Acad Sci USA 109(1):197–202. https://doi.org/10.1073/pnas.1104767109 CrossRefPubMed

35.

Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, Lahusen T, Xu X, Lee MH, Liu Q, Elledge SJ, Ried T, Deng CX (2010) Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29(28):4007–4017. https://doi.org/10.1038/onc.2010.163 CrossRefPubMedPubMedCentral

36.

Niida H, Murata K, Shimada M, Ogawa K, Ohta K, Suzuki K, Fujigaki H, Khaw AK, Banerjee B, Hande MP, Miyamoto T, Miyoshi I, Shirai T, Motoyama N, Delhase M, Appella E, Nakanishi M (2010) Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. EMBO J 29(20):3558–3570. https://doi.org/10.1038/emboj.2010.218 CrossRefPubMedPubMedCentral

37.

Tort F, Hernandez S, Bea S, Camacho E, Fernandez V, Esteller M, Fraga MF, Burek C, Rosenwald A, Hernandez L, Campo E (2005) Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19(1):112–117. https://doi.org/10.1038/sj.leu.2403571 CrossRefPubMed

38.

Check JH, Check D, Cohen R, Sarumi M (2014) Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor. Anticancer Res 34(5):2413–2416PubMed

39.

Check JH, DiAntonio G, DiAntonio A, Duroseau M (2016) The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone. Clin Exp Obstet Gynecol 43(2):189–191PubMed

Title: PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells
Authors: Eun Ji Ro
Seung-Hee Ryu
Eun-Young Park
Je-Won Ryu
Sang Jun Byun
Seung-Ho Heo
Kang Hyun Kim
In-Jeoung Baek
Byung Ho Son
Sang-Wook Lee
Publication date: 01-08-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05732-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients

Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?

Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

The effect of 1-day multidisciplinary clinic on breast cancer treatment

High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer